Literature DB >> 7207769

Central nervous system metastases in malignant melanoma.

D E Bullard, E B Cox, H F Seigler.   

Abstract

In a series of 1341 patients with histologically proven malignant melanoma seen at Duke University Medical Center from 1968 to 1978, 107 patients developed central nervous system (CNS) metastases. These patients were evaluated on the basis of which factors were associated with the development of CNS metastases. Male patients, patients with invasive primary lesions as measured by Clark's system, and patients with primary lesions of the head/neck or oral mucosa had higher incidences of CNS metastasis. Age and race were not significant factors. Clinically, single CNS metastases were seen in 48.8% of the patients; multiple cerebral lesions were seen in 37.2% of the patients. In 22% of the patients there was CNS metastasis alone, in 41% a second organ was involved, and in 20% three organs were involved.

Entities:  

Mesh:

Year:  1981        PMID: 7207769     DOI: 10.1227/00006123-198101000-00006

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  21 in total

1.  Effects of FOXM1 inhibition and ionizing radiation on melanoma cells.

Authors:  Vivienne S Lee; Lucinda S McRobb; Vaughan Moutrie; Estavam D Santos; Timothy L Siu
Journal:  Oncol Lett       Date:  2018-09-21       Impact factor: 2.967

2.  Malignant perivascular melanoma mimicking primary central nervous system vasculitis.

Authors:  Martin Schneider; Jan Höltje; Uwe Kehler; Volker Hartmann; Konstanze Holl-Ullrich; Katrin Oechel; Peter Paul Urban
Journal:  J Neurol       Date:  2012-12-20       Impact factor: 4.849

3.  Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases.

Authors:  Maja Hofmann; Felix Kiecker; Reinhard Wurm; Lorenz Schlenger; Volker Budach; Wolfram Sterry; Uwe Trefzer
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

4.  It is never too late: ultra-late recurrence of melanoma with distant metastases.

Authors:  Dina Mansour; Deepak Kejariwal
Journal:  BMJ Case Rep       Date:  2012-03-08

5.  Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma.

Authors:  Ahmad A Tarhini; Siyang Leng; Stergios J Moschos; Yan Yin; Cindy Sander; Yan Lin; William E Gooding; John M Kirkwood
Journal:  J Immunother       Date:  2012-05       Impact factor: 4.456

6.  Predictive factors for the development of brain metastases in patients with malignant melanoma: a study by the Anatolian society of medical oncology.

Authors:  Ozge Gumusay; Ugur Coskun; Tülay Akman; Ahmet Siyar Ekinci; Muharrem Kocar; Ozlem Balvan Erceleb; Ozan Yazıcı; Mehmet Ali Kaplan; Veli Berk; Bulent Cetin; Burcu Yapar Taskoylu; Ayhan Yildiz; Gamze Goksel; Ahmet Alacacioglu; Umut Demirci; Efnan Algin; Mukremin Uysal; Ilhan Oztop; Berna Oksuzoglu; Faysal Dane; Mahmut Gumus; Suleyman Buyukberber
Journal:  J Cancer Res Clin Oncol       Date:  2013-11-29       Impact factor: 4.553

7.  Prognostic evaluation of intracranial metastasis in malignant melanoma.

Authors:  S Saha; M Meyer; E T Krementz; S Hoda; R D Carter; J Muchmore; C Sutherland
Journal:  Ann Surg Oncol       Date:  1994-01       Impact factor: 5.344

8.  Myelopathy from Intradural Extramedullary Metastasis as an Initial Presentation of Metastatic Melanoma.

Authors:  Alan A Stein; Gila R Weinstein; Colin Niezgoda; Sajeel Chowdhary; Frank Vrionis; John K Houten
Journal:  Cureus       Date:  2018-05-22

9.  MiR-92b and miR-9/9* are specifically expressed in brain primary tumors and can be used to differentiate primary from metastatic brain tumors.

Authors:  Dvora Nass; Shai Rosenwald; Eti Meiri; Shlomit Gilad; Hilla Tabibian-Keissar; Anat Schlosberg; Hagit Kuker; Netta Sion-Vardy; Ana Tobar; Oleg Kharenko; Einat Sitbon; Gila Lithwick Yanai; Eran Elyakim; Hila Cholakh; Hadas Gibori; Yael Spector; Zvi Bentwich; Iris Barshack; Nitzan Rosenfeld
Journal:  Brain Pathol       Date:  2008-07-02       Impact factor: 6.508

10.  Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system.

Authors:  Heidi V N Küsters-Vandevelde; Annelies Klaasen; Benno Küsters; Patricia J T A Groenen; Ilse A C H van Engen-van Grunsven; Marcory R C F van Dijk; Guido Reifenberger; Pieter Wesseling; Willeke A M Blokx
Journal:  Acta Neuropathol       Date:  2010-03       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.